Sanofi - American Depositary Shares (NQ:SNY)

39.72 -0.20 (-0.50%)

Delayed Quote Updated: 3:41 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

42 43 Next >

Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗

February 02, 2024

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.

Via Benzinga

Sanofi (SNY) Q4 2023 Earnings Call Transcript ↗

February 01, 2024

SNY earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 01, 2024

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

Via Benzinga

Sanofi's Earnings Outlook ↗

January 31, 2024

Via Benzinga

Analyzing NASDAQ:SNY's Dividend Potential. ↗

January 24, 2024

Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY).

Via Chartmill

Why NASDAQ:SNY is a Top Pick for Dividend Investors. ↗

January 02, 2024

Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential.

Via Chartmill

French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs ↗

February 01, 2024

Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge.

Via Benzinga

Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. ↗

February 01, 2024

The company missed total sales and earnings expectations.

Via Investor's Business Daily

Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year ↗

February 01, 2024

After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February.

Via Benzinga

MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

February 01, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.

Via Benzinga

Looking Into Sanofi's Recent Short Interest ↗

December 21, 2023

Via Benzinga

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation ↗

January 26, 2024

FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.

Via Benzinga

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

January 25, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx ↗

January 23, 2024

The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.

Via Investor's Business Daily

French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B ↗

January 23, 2024

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected...

Via Benzinga

Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project ↗

January 23, 2024

Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.

Via Benzinga

Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades ↗

January 22, 2024

HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.

Via Benzinga

Time to buy these 3 healthcare companies that raised revenue guidance?

January 16, 2024

The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.

Via MarketBeat

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation ↗

January 10, 2024

French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger...

Via Benzinga

Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering ↗

January 05, 2024

Shares soared and then tumbled Friday after the company offered $275 million in public shares.

Via Investor's Business Daily

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗

January 04, 2024

More than 140 brands of drugs are going to see their prices hiked heading into the new year

Via Talk Markets

China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants ↗

January 02, 2024

Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD

Via Benzinga

Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗

December 29, 2023

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...

Via Benzinga

NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

December 28, 2023

SANOFI-ADR (NASDAQ:SNY): good value for what you're paying.

Via Chartmill

Why First Wave BioPharma Shares Are Skyrocketing Today ↗

December 27, 2023

First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of

Via Benzinga

Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? ↗

December 21, 2023

MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan

Via Benzinga

European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data ↗

December 21, 2023

Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.